Theseus Pharmaceuticals to Participate Virtually in Wedbush PacGrow Healthcare Conference

Rhea-AI Summary

Theseus Pharmaceuticals (NASDAQ: THRX) will participate virtually in the 2022 Wedbush PacGrow Healthcare Conference on August 10, 2022, at 10:20 AM ET for a panel discussion. The event will be accessible via a live webcast on the company's investor relations website, with an archived version available for 30 days. The management team will also engage in one-on-one meetings with investors during the conference. Theseus focuses on developing targeted therapies to combat cancer, including its lead candidate, THE-630, aimed at advanced gastrointestinal stromal tumors.

CAMBRIDGE, Mass., Aug. 3, 2022 /PRNewswire/ -- Theseus Pharmaceuticals, Inc. (NASDAQ: THRX) (Theseus or the Company), a clinical-stage biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development and commercialization of transformative targeted therapies, today announced that it will participate virtually in the 2022 Wedbush PacGrow Healthcare Conference, taking place August 9-10, 2022.

Presentation Details:
Event: Wedbush PacGrow Healthcare Conference
Date / Time: Wednesday, August 10^th, 2022, at 10:20am ET
Format: Panel Discussion

A live webcast will be available in the Events section of the company's investor relations website at ir.theseusrx.com and archived for 30 days following the presentation.

Management will also be participating in one-on-one investor meetings throughout the conference. Investors interested in scheduling a meeting with the Theseus management team should contact their Wedbush representative.

About Theseus Pharmaceuticals, Inc.

Theseus is a clinical-stage biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development and commercialization of transformative targeted therapies. Theseus is working to outsmart cancer resistance by developing pan-variant tyrosine kinase inhibitors (TKIs) to target all known classes of cancer-causing and resistance mutations that lead to variants in a particular protein in a given type of cancer. Theseus' lead product candidate, THE-630, is a pan-variant KIT inhibitor for the treatment of patients with advanced gastrointestinal stromal tumors (GIST), whose cancer has developed resistance to earlier lines of kinase inhibitor therapy. Theseus is also developing a fourth-generation, selective epidermal growth factor receptor (EGFR) inhibitor for C797S-mediated resistance to first- or later-line osimertinib treatment in patients with non-small cell lung cancer (NSCLC). For more information, visit www.theseusrx.com.

Media Contact
Amy Jobe, Ph.D.
LifeSci Communications
315-879-8192
ajobe@lifescicomms.com

Investor Contact
Christen Baglaneas
Theseus Pharmaceuticals
857-706-4993
christen.baglaneas@theseusrx.com

Josh Rappaport
Stern Investor Relations
212-362-1200
josh.rappaport@sternir.com

View original content:https://www.prnewswire.com/news-releases/theseus-pharmaceuticals-to-participate-virtually-in-wedbush-pacgrow-healthcare-conference-301598489.html

SOURCE Theseus Pharmaceuticals

FAQ

When is Theseus Pharmaceuticals participating in the Wedbush PacGrow Healthcare Conference?

Theseus Pharmaceuticals will participate in the Wedbush PacGrow Healthcare Conference on August 10, 2022.

What time will Theseus Pharmaceuticals present at the Wedbush Conference?

Theseus Pharmaceuticals will present at 10:20 AM ET on August 10, 2022.

How can I watch the Theseus Pharmaceuticals presentation?

The presentation can be watched live through the company's investor relations website and will be archived for 30 days.

What is the focus of Theseus Pharmaceuticals' research?

Theseus Pharmaceuticals focuses on developing transformative targeted therapies for cancer treatment.

What is the lead product candidate of Theseus Pharmaceuticals?

The lead product candidate of Theseus Pharmaceuticals is THE-630, a pan-variant KIT inhibitor for advanced gastrointestinal stromal tumors.